JP2008512987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512987A5 JP2008512987A5 JP2007522034A JP2007522034A JP2008512987A5 JP 2008512987 A5 JP2008512987 A5 JP 2008512987A5 JP 2007522034 A JP2007522034 A JP 2007522034A JP 2007522034 A JP2007522034 A JP 2007522034A JP 2008512987 A5 JP2008512987 A5 JP 2008512987A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- domain
- heavy chain
- binding
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 238000000034 method Methods 0.000 claims 11
- 230000027455 binding Effects 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 7
- 230000009261 transgenic effect Effects 0.000 claims 7
- 101150097493 D gene Proteins 0.000 claims 4
- 101150008942 J gene Proteins 0.000 claims 4
- 101150117115 V gene Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 241000282836 Camelus dromedarius Species 0.000 claims 2
- 230000009824 affinity maturation Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010069754 Acquired gene mutation Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 230000037439 somatic mutation Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0416392A GB2416768A (en) | 2004-07-22 | 2004-07-22 | Heavy chain immunoglobulin complexes |
| GB0511881A GB0511881D0 (en) | 2005-06-10 | 2005-06-10 | Binding molecules |
| PCT/GB2005/002892 WO2006008548A2 (en) | 2004-07-22 | 2005-07-22 | Binding molecules |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011166561A Division JP5855381B2 (ja) | 2004-07-22 | 2011-07-29 | 結合分子 |
| JP2011166562A Division JP5888893B2 (ja) | 2004-07-22 | 2011-07-29 | 結合分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512987A JP2008512987A (ja) | 2008-05-01 |
| JP2008512987A5 true JP2008512987A5 (https=) | 2008-11-13 |
Family
ID=35431831
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522034A Pending JP2008512987A (ja) | 2004-07-22 | 2005-07-22 | 結合分子 |
| JP2011166562A Expired - Fee Related JP5888893B2 (ja) | 2004-07-22 | 2011-07-29 | 結合分子 |
| JP2011166561A Expired - Lifetime JP5855381B2 (ja) | 2004-07-22 | 2011-07-29 | 結合分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011166562A Expired - Fee Related JP5888893B2 (ja) | 2004-07-22 | 2011-07-29 | 結合分子 |
| JP2011166561A Expired - Lifetime JP5855381B2 (ja) | 2004-07-22 | 2011-07-29 | 結合分子 |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US20090285805A1 (https=) |
| EP (6) | EP1864998B2 (https=) |
| JP (3) | JP2008512987A (https=) |
| KR (4) | KR101422286B1 (https=) |
| CN (2) | CN102659940B (https=) |
| AU (2) | AU2005263994B2 (https=) |
| BR (1) | BRPI0513577A (https=) |
| CA (1) | CA2580336C (https=) |
| CY (2) | CY1115762T1 (https=) |
| DK (3) | DK2311874T3 (https=) |
| ES (3) | ES2635497T3 (https=) |
| HU (1) | HUE034335T2 (https=) |
| LT (1) | LT2311874T (https=) |
| MX (2) | MX2007000921A (https=) |
| PL (2) | PL1776383T3 (https=) |
| PT (2) | PT1776383E (https=) |
| RU (1) | RU2398882C2 (https=) |
| SG (1) | SG188080A1 (https=) |
| SI (2) | SI2311874T1 (https=) |
| WO (1) | WO2006008548A2 (https=) |
| ZA (3) | ZA200701186B (https=) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| SI2311874T1 (sl) * | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| HRP20140338T1 (hr) | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| GB0601513D0 (en) * | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
| GB0618345D0 (en) * | 2006-09-18 | 2006-10-25 | Univ Erasmus | Binding molecules |
| TWI404727B (zh) | 2006-01-25 | 2013-08-11 | 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 | 對偶基因排除 |
| WO2007146968A2 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| GB0706628D0 (en) * | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| WO2009013620A2 (en) * | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| EP2173772A2 (en) * | 2007-07-03 | 2010-04-14 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating cdr and/or fr positions |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| ES2526433T3 (es) | 2007-12-26 | 2015-01-12 | Biotest Ag | Inmunoconjugados dirigidos a CD138 y usos de los mismos |
| EP2240516B1 (en) | 2007-12-26 | 2015-07-08 | Biotest AG | Methods and agents for improving targeting of cd138 expressing tumor cells |
| CA2710453C (en) | 2007-12-26 | 2019-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
| AU2009235467A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Single variable domains against the Notch pathways |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| NZ589036A (en) | 2008-05-16 | 2012-07-27 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| ES2436044T3 (es) | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
| AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
| EP3470425A3 (en) | 2008-12-19 | 2019-07-17 | Ablynx N.V. | Immunoglobulins against cell-associatd antigens such as p2x7 |
| WO2010079149A1 (de) | 2009-01-09 | 2010-07-15 | Ipk Gatersleben | Fusionsantikörper |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| US8754287B2 (en) * | 2009-12-10 | 2014-06-17 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| EP2513145B1 (en) | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| CN102946906B (zh) * | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
| SG10201912639SA (en) * | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| EA202092589A3 (ru) | 2010-11-08 | 2021-06-30 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
| WO2012122512A1 (en) * | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| US9433620B2 (en) | 2011-05-13 | 2016-09-06 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| WO2013121440A1 (en) | 2012-02-13 | 2013-08-22 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates |
| PT2825559T (pt) | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
| GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| HRP20231356T1 (hr) | 2012-12-14 | 2024-02-16 | Omniab, Inc. | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
| US9980470B2 (en) | 2013-03-14 | 2018-05-29 | Erasmus University Medical Center | Antibody production |
| US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| JP6721505B2 (ja) * | 2013-09-05 | 2020-07-15 | アイジーエム バイオサイエンシズ インコーポレイテッド | 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体 |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| JP2017512208A (ja) * | 2014-02-10 | 2017-05-18 | アイジーエム バイオサイエンス， インコーポレイテッド | ＩｇＡ多重特異性結合分子 |
| ES2800674T3 (es) * | 2014-03-21 | 2021-01-04 | X Body Inc | Polipéptidos biespecíficos de unión a antígeno |
| KR102276752B1 (ko) | 2014-03-21 | 2021-07-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| CA2943707A1 (en) | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
| JP6641379B2 (ja) | 2014-10-22 | 2020-02-05 | クレシェンド・バイオロジックス・リミテッド | トランスジェニックマウス |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| US10266589B2 (en) | 2015-07-29 | 2019-04-23 | Allergan, Inc. | Heavy chain only antibodies to ANG-2 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017030909A1 (en) | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| EP3352760B1 (en) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| IL264941B2 (en) * | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| EP3332637A1 (en) * | 2016-12-09 | 2018-06-13 | Universitätsklinikum Hamburg-Eppendorf | Vhh-containing heavy chain antibody and production thereof |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| NZ755816A (en) | 2017-01-19 | 2026-03-27 | Omniab Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| KR20200044094A (ko) | 2017-09-13 | 2020-04-28 | 테네오바이오, 인코포레이티드 | 엑토효소에 결합하는 중쇄 항체 |
| BR112020012364A2 (pt) | 2017-12-20 | 2020-11-24 | Harbour Biomed (Shanghai) Co., Ltd | anticorpos de ligação a ctla-4 e usos dos mesmos |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對ｔｉｇｉｔ之單域抗體及其變異體 |
| EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1 |
| AU2019241350B2 (en) | 2018-03-30 | 2025-10-02 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
| KR102115300B1 (ko) | 2018-06-01 | 2020-05-26 | 재단법인 목암생명과학연구소 | 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법 |
| EP3801772A1 (en) * | 2018-06-11 | 2021-04-14 | Aarhus Universitet | Single domain antibodies for complement regulation |
| AU2019284252B2 (en) | 2018-06-13 | 2025-10-09 | Crystal Bioscience Inc. | Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| GB2576914A (en) | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
| US12097219B2 (en) | 2018-09-10 | 2024-09-24 | Legend Biotech Ireland Limited | Single-domain antibodies against CLL1 and constructs thereof |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| BR112021000173A2 (pt) | 2018-10-26 | 2021-05-04 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd38 |
| CN113874394B (zh) | 2019-02-20 | 2024-01-19 | 和铂抗体有限公司 | 抗体 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| MA56110A (fr) | 2019-06-07 | 2022-04-13 | Amgen Inc | Constructions de liaison bispécifiques à lieurs clivables de manière sélective |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| JP2022545541A (ja) * | 2019-08-28 | 2022-10-27 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| WO2021127489A1 (en) | 2019-12-18 | 2021-06-24 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
| AU2021263448B2 (en) | 2020-04-29 | 2026-02-05 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| TWI838621B (zh) | 2020-04-29 | 2024-04-11 | 美商泰尼歐萬公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| CA3185805A1 (en) | 2020-04-29 | 2021-11-04 | Teneoone, Inc. | Methods of treating multiple myeloma |
| CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
| US20230242658A1 (en) * | 2020-06-30 | 2023-08-03 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1bb-binding protein and use thereof |
| IL299027A (en) | 2020-06-30 | 2023-02-01 | Teneobio Inc | Multispecific antibodies that bind BCMA |
| US20230270086A1 (en) * | 2020-07-13 | 2023-08-31 | Kisoji Biotechnology Inc. | Transgenic animals expressing heavy chain antibodies |
| CA3187680A1 (en) | 2020-09-11 | 2022-03-17 | Yashu Liu | Identification and production of antigen-specific antibodies |
| GB202017555D0 (en) | 2020-11-06 | 2020-12-23 | Harbour Antibodies Bv | Antibody-conjugated nanoparticles |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| EP4255931A1 (en) | 2020-12-03 | 2023-10-11 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| CA3204101A1 (en) * | 2020-12-09 | 2022-06-16 | Trianni, Inc. | Heavy chain-only antibodies |
| WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CA3209052A1 (en) | 2021-02-19 | 2022-08-25 | Rafael Cristian CASELLAS | Single domain antibodies that neutralize sars-cov-2 |
| CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
| WO2022183101A1 (en) | 2021-02-26 | 2022-09-01 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| PE20232050A1 (es) | 2021-04-06 | 2023-12-27 | Teneobio Inc | Anticuerpos anti-cd19 y estructuras car-t |
| WO2022221698A1 (en) | 2021-04-16 | 2022-10-20 | Teneobio, Inc. | Anti-cd20 antibodies and car-t structures |
| JP7799706B2 (ja) * | 2021-05-05 | 2026-01-15 | レヴェラージェン，インコーポレーテッド | 抗体を産生するための組換え非ヒト動物 |
| CN117651486A (zh) * | 2021-05-05 | 2024-03-05 | 利威瑞健股份有限公司 | 用于生产抗体的工程改造的非人动物 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
| WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
| EP4598958A1 (en) | 2022-10-05 | 2025-08-13 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| EP4605077A1 (en) | 2022-10-18 | 2025-08-27 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| EP4512243A1 (en) | 2023-08-21 | 2025-02-26 | Kymab Limited | Binding molecules |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗ｉｌ－２ｒｂｇ重鏈抗體 |
| GB202406483D0 (en) | 2024-05-09 | 2024-06-26 | Harbour Antibodies Bv | Crossing the blood brain barrier to treat diseases of the brain |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026035843A2 (en) | 2024-08-06 | 2026-02-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0144488A3 (en) | 1980-08-11 | 1985-07-10 | BAUSCH & LOMB INCORPORATED | Apparatus for supporting and positioning the halves of a refractor |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
| AU8869291A (en) | 1990-10-04 | 1992-04-28 | University Of Virginia Alumni Patents Foundation, The | Primate erythrocyte bound monoclonal antibody heteropolymers |
| AU701578B2 (en) * | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| WO1998021355A1 (en) * | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| EP0954978B1 (en) * | 1998-03-12 | 2011-11-30 | VHsquared Limited | New products comprising inactivated yeasts or moulds provided with active antibodies |
| US7083950B2 (en) † | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| EA013564B1 (ru) * | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| AU2001278154A1 (en) | 2000-08-04 | 2002-02-18 | Incyte Genomics, Inc. | Drug metabolizing enzymes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| NZ530212A (en) | 2001-06-13 | 2006-09-29 | Genmab As | An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| US6880232B2 (en) | 2001-09-26 | 2005-04-19 | Intel Corporation | Method of making an electrical inductor using a sacrificial electrode |
| JP2005289809A (ja) * | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US6755339B2 (en) † | 2002-06-21 | 2004-06-29 | Delphi Technologies, Inc. | Fluxing apparatus for applying powdered flux |
| ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| GB0218030D0 (en) | 2002-08-02 | 2002-09-11 | Minos Biosystems | Multi-submit protein production system |
| GB0228210D0 (en) * | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| WO2005070966A2 (en) † | 2004-01-16 | 2005-08-04 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| SI2311874T1 (sl) * | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20080184380A1 (en) | 2004-10-22 | 2008-07-31 | Therapeutic Human Polyclonals Inc. | Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| ES2852423T3 (es) | 2005-05-20 | 2021-09-13 | Ablynx Nv | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| TWI404727B (zh) * | 2006-01-25 | 2013-08-11 | 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 | 對偶基因排除 |
| GB0618345D0 (en) * | 2006-09-18 | 2006-10-25 | Univ Erasmus | Binding molecules |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| US7731969B1 (en) | 2006-12-06 | 2010-06-08 | Neoclone Biotechnology International, Llc | Methods for developing and producing antigen-specific antibody-producing cells |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US8754287B2 (en) | 2009-12-10 | 2014-06-17 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| RU2722373C2 (ru) | 2011-02-25 | 2020-05-29 | Редженерон Фармасьютикалс, Инк. | Мыши adam6 |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| HRP20231356T1 (hr) | 2012-12-14 | 2024-02-16 | Omniab, Inc. | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
| US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
-
2005
- 2005-07-22 SI SI200532162T patent/SI2311874T1/sl unknown
- 2005-07-22 DK DK10179784.3T patent/DK2311874T3/en active
- 2005-07-22 ES ES10179784.3T patent/ES2635497T3/es not_active Expired - Lifetime
- 2005-07-22 EP EP07075586.3A patent/EP1864998B2/en not_active Expired - Lifetime
- 2005-07-22 EP EP05766644.8A patent/EP1776383B1/en not_active Revoked
- 2005-07-22 CA CA2580336A patent/CA2580336C/en not_active Expired - Lifetime
- 2005-07-22 LT LTEP10179784.3T patent/LT2311874T/lt unknown
- 2005-07-22 SI SI200531906T patent/SI1776383T1/sl unknown
- 2005-07-22 SG SG2013004643A patent/SG188080A1/en unknown
- 2005-07-22 PL PL05766644T patent/PL1776383T3/pl unknown
- 2005-07-22 ES ES07075586T patent/ES2440990T5/es not_active Expired - Lifetime
- 2005-07-22 KR KR1020077004055A patent/KR101422286B1/ko not_active Expired - Lifetime
- 2005-07-22 MX MX2007000921A patent/MX2007000921A/es active IP Right Grant
- 2005-07-22 EP EP23218163.6A patent/EP4353819A3/en not_active Withdrawn
- 2005-07-22 KR KR1020127016031A patent/KR101443473B1/ko not_active Expired - Lifetime
- 2005-07-22 EP EP08075481A patent/EP1978032A3/en not_active Withdrawn
- 2005-07-22 JP JP2007522034A patent/JP2008512987A/ja active Pending
- 2005-07-22 WO PCT/GB2005/002892 patent/WO2006008548A2/en not_active Ceased
- 2005-07-22 PL PL10179784T patent/PL2311874T3/pl unknown
- 2005-07-22 CN CN201210057668.0A patent/CN102659940B/zh not_active Expired - Lifetime
- 2005-07-22 CN CN201210057684.XA patent/CN102659941B/zh not_active Expired - Lifetime
- 2005-07-22 PT PT57666448T patent/PT1776383E/pt unknown
- 2005-07-22 PT PT101797843T patent/PT2311874T/pt unknown
- 2005-07-22 DK DK05766644.8T patent/DK1776383T3/da active
- 2005-07-22 KR KR1020107026625A patent/KR101151957B1/ko not_active Expired - Lifetime
- 2005-07-22 US US11/658,361 patent/US20090285805A1/en not_active Abandoned
- 2005-07-22 AU AU2005263994A patent/AU2005263994B2/en not_active Expired
- 2005-07-22 EP EP17173113.6A patent/EP3272770B1/en not_active Expired - Lifetime
- 2005-07-22 ES ES05766644.8T patent/ES2523661T3/es not_active Expired - Lifetime
- 2005-07-22 RU RU2007106728/13A patent/RU2398882C2/ru active
- 2005-07-22 EP EP10179784.3A patent/EP2311874B1/en not_active Expired - Lifetime
- 2005-07-22 KR KR1020117019563A patent/KR101457753B1/ko not_active Ceased
- 2005-07-22 HU HUE10179784A patent/HUE034335T2/en unknown
- 2005-07-22 DK DK07075586.3T patent/DK1864998T4/da active
- 2005-07-22 BR BRPI0513577-0A patent/BRPI0513577A/pt active Search and Examination
-
2007
- 2007-01-22 MX MX2012000436A patent/MX338603B/es unknown
- 2007-02-09 ZA ZA2007/01186A patent/ZA200701186B/en unknown
-
2008
- 2008-02-26 ZA ZA2008/01820A patent/ZA200801820B/en unknown
-
2009
- 2009-12-23 US US12/645,684 patent/US8921524B2/en active Active
- 2009-12-23 US US12/645,653 patent/US8921522B2/en active Active
-
2010
- 2010-08-24 AU AU2010212518A patent/AU2010212518B2/en not_active Expired
-
2011
- 2011-01-25 US US13/013,156 patent/US20110118444A1/en not_active Abandoned
- 2011-07-29 JP JP2011166562A patent/JP5888893B2/ja not_active Expired - Fee Related
- 2011-07-29 JP JP2011166561A patent/JP5855381B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-25 ZA ZA2013/01416A patent/ZA201301416B/en unknown
- 2013-03-15 US US13/837,402 patent/US9353179B2/en not_active Expired - Lifetime
- 2013-03-15 US US13/837,520 patent/US9346877B2/en not_active Expired - Lifetime
-
2014
- 2014-11-17 CY CY20141100953T patent/CY1115762T1/el unknown
-
2017
- 2017-08-11 CY CY20171100869T patent/CY1119561T1/el unknown
-
2018
- 2018-04-16 US US15/953,622 patent/US10906970B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008512987A5 (https=) | ||
| JP2018138047A5 (https=) | ||
| JP7171853B2 (ja) | 免疫グロブリン産生の増強 | |
| JP2015519055A5 (https=) | ||
| EP3341485B1 (en) | Enhanced production of immunoglobulins | |
| CN104244709B (zh) | 共同轻链小鼠 | |
| JP2020530760A5 (https=) | ||
| WO2014160202A4 (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| JP2013535213A5 (https=) | ||
| JP2010529042A5 (https=) | ||
| RU2014153673A (ru) | Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина | |
| JP2015519076A5 (https=) | ||
| JP2015525071A5 (https=) | ||
| JP2014110814A5 (https=) | ||
| RU2012128856A (ru) | Мыши, которые производят антитела, имеющие только тяжелую цепь | |
| JP2015510767A5 (https=) | ||
| RU2021129958A (ru) | Отличные от человека животные со сконструированным локусом легкой лямбда-цепи иммуноглобулина | |
| JP2013513388A5 (https=) | ||
| RU2016139418A (ru) | Мыши с ограниченной тяжелой цепью иммуноглобулина | |
| JP2016512034A5 (https=) | ||
| WO2015042250A4 (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same | |
| JP7085992B2 (ja) | 共通軽鎖を有するトランスジェニックウサギ | |
| WO2022048604A1 (zh) | 一种非人哺乳动物或其子代的制备方法及其应用 | |
| CA3259663A1 (en) | ANIMAL MODELS AND THERAPEUTIC MOLECULES | |
| CA3012833C (en) | Enhanced production of immunoglobulins |